v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

Note 9 – Segment Reporting

 

The Company has two reportable segments: digital asset treasury and clinical stage bio-technology.

 

The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial performance of the business and makes resource allocation decisions on the basis of net income/(loss) before income taxes.

 

Summary segment financial performance measures evaluated by the CODM as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025:

 

       
   Segment Assets 
   June 30, 2026   December 31, 2025 
Digital asset treasury segment  $563,869,389   $513,964,900 
Clinical stage bio-technology segment – continuing operations   -    - 
Clinical stage bio-technology segment – held for sale   700,997    5,181,535 
Total assets  $564,570,386   $519,146,435 

 

Digital asset treasury segment

 

             
   For the three months ended June 30,   For the six months ended June 30, 
   2026   2025   2026   2025 
Loss from operations  $(1,202,154)  $-   $(36,423,335)  $- 
Other income (expense) (a)   311,848    -    630,026    - 
Unrealized loss on digital assets holdings   (23,735,950)   -    (38,749,254)   - 
Total loss before income taxes  $(24,626,256)  $-   $(74,542,563)  $- 

 

Clinical stage bio-technology segment

 

             
   For the three months ended June 30,   For the six months ended June 30, 
   2026   2025   2026   2025 
Loss from operations – continuing operations  $-   $(1,428,594)  $-   $(3,472,642)
Loss from operations – discontinued operations   (1,300,745)   (422,566)   (2,947,875)   (925,187)
Other income (expense) (a)   -    (3,993)   -    972 
Total loss before income taxes  $(1,300,745)  $(1,855,153)  $(2,947,875)  $(4,396,857)

 

  (a) Other income (expense) consists of interest income and interest expense.

 

The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.

 

             
   For the three months ended June 30,   For the six months ended June 30, 
   2026   2025   2026   2025 
Digital asset treasury segment total loss before income taxes  $(24,626,256)  $-   $(74,542,563)  $- 
Clinical stage bio-technology segment total loss before income taxes – continuing operations   -    (1,432,587)        (3,471,670)
Clinical stage bio-technology segment total loss before income taxes – discontinued operations   (1,300,745)   (422,566)   (2,947,875)   (925,187)
Consolidated total loss before income taxes  $(25,927,001)  $(1,855,153)  $(77,490,438)  $(4,396,857)